Synexus expansion across Eastern Europe, adds three new clinical trial centers
Synexus continues to expand across Eastern Europe with three new Dedicated Research Centers in Bulgaria, Poland and Romania, bringing the total to nine centers in Eastern Europe and a total network of 25 across Europe and Africa. These new centers will provide the company’s clients in pharma and CROs with an expanding pool of patients.
The population of Central and Eastern European countries exceeds that of either the U.S. or the five largest Western European markets combined, coupled with its excellent healthcare professionals, which is the reason it has continued to remain important to the clinical trials market.
Synexus, which is based in the U.K., is a multi-national company entirely focused on the recruitment and running of clinical trials at its own 25 dedicated research centers and 24 affiliated sites.
Christophe Berthoux, CEO at Synexus, said, “This is our ninth Dedicated Research Center in Eastern Europe, which will help us to provide much greater support to the global pharmaceutical industry. Since we opened our first center in Poland in 2006, we have had an ongoing program of investment in the region. Throughout the world we are upgrading our centers to provide the very latest facilities for our patients and to provide our clients in pharma with the most accurate data.”
The new Polish facility is Synexus’ largest research center in the world. Dr. Magdalena Przekwas-Jaruchowska is the center’s director.
Romania’s new center is based in the capital, Bucharest, which has a population of two million. Romania has been part of Synexus’ development plans since early 2000, as the country’s total population is over 20 million and the number of new clinical trials which has been granted approval during the last five years is at least 200.
The dedicated research center in Bulgaria is situated in Sofia with eight medical rooms, two administration rooms, monitoring and meeting rooms and other areas. This is an innovative project for Bulgaria, which aims to offer its patients access to new drugs including the fields of pulmonology, rheumatology, neurology, endochrinology, cardiology, gastroenterology and dermatology.
All Synexus’ 25 clinics across Europe and Africa focus on undertaking clinical trials in the therapy areas where the company can provide most value. Particular attention is devoted to the areas of cardiovascular, metabolic (diabetes and obesity), musculoskeletal, respiratory and central nervous system (dementia and pain) trials.